AstraZeneca PLC (AZN)vsConcentra Group Holdings Parent, Inc. (CON)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CON
Concentra Group Holdings Parent, Inc.
$22.47
+0.36%
HEALTHCARE · Cap: $2.90B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2615% more annual revenue ($58.74B vs $2.16B). AZN leads profitability with a 17.4% profit margin vs 7.7%. CON trades at a lower P/E of 17.4x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CON
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+66.5%
Fair Value
$72.22
Current Price
$22.47
$49.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 48 in profit
Earnings expanding 60.1% YoY
Attractively priced relative to earnings
15.9% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
7.7% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth, P/E Ratio. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while CON is a growth play — different risk/reward profiles.
CON is growing revenue faster at 15.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 59/100), backed by strong 17.4% margins. CON offers better value entry with a 66.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company that specializes in acquiring and managing businesses in high-growth sectors such as healthcare, technology, and infrastructure. With a commitment to operational excellence and innovation, Concentra leverages its seasoned leadership team to enhance portfolio performance through strategic investments and proactive management. This forward-looking approach positions the company to effectively capitalize on emerging trends and opportunities, making it an attractive investment for institutional investors aiming to diversify into high-potential industries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?